2022 Revenues ($USD) : $5,232,500,000
2022 R&D spend : $903,100,000
2022 Number of Employees : 15,700
Fiscal Year End : 12/31/2021
Company CEO : Michael Mussallem, CEO

Edwards Lifesciences is one of medtech's biggest heart valve makers. The Irvine, California–based company treats advanced cardiovascular disease with its numerous heart valve therapies and critical care and vascular technologies. One of Edwards' most known specialties is its transcatheter aortic valve replacement (TAVR) devices. The medtech giant also specializes in blood conservation, enhanced surgical recovery, clot management, hypotension management, infection control and sepsis shock management. In 2022, the company won FDA approval for its Mitris Resilia tissue valve replacement system but continued to face headwinds from hospital staffing shortages. Edwards Lifesciences expects FDA approval of its Pascal Precision platform later this year. –DK and JH